ETHICS ADVISORY BOARD
Illumina is committed to building our company with integrity and ethical business behavior.
What is Illumina’s Ethics
Advisory Board?
Since 2008, Illumina convened anEthics Advisory Board (EAB) to ensurethat Illumina acts ethically and justly
in its business operations. The EAB
meets quarterly to advise and provide
recommendations regarding ethicalissues involving Illumina’s existing,emerging, and prospective products,services, and processes both from a
research and clinical perspective. This
includes providing strategic advice toIllumina regarding emerging ethicalissues, policies, and regulations relevantto the genomics industry.

Clement Adebamowo, BM,ChB, ScD, FWACS, FACS
Clement Adebamowo is Professor ofEpidemiology, Associate Director ofPopulation Science and Director for Global
Health Cancer Research at the Greenebaum
Comprehensive Cancer Center, and memberof the Institute of Human Virology at the University of Maryland
School of Medicine. He was foundation chair of the Nigerian National
Health Research Ethics Committee, Principal Investigator of several
NIH-funded genomics, cancer and bioethics research and training
projects including the Indigene Study, a project for improvement ofcomprehension of informed consent for genomic ethics in African
communities that incorporates an online database of words related togenomics in local African languages.

Leslie Biesecker, M.D.
Les is a clinical and molecular geneticist andis the chief of the Medical Genomics andMetabolic Genetics Branch at the National
Human Genome Research Institute (NHGRI)
of the National Institutes of Health. Dr.
Biesecker directs the ClinSeq project withgoals to improve medical care for patients and provide generalized
knowledge about genetic disease. He is a member of the National
Academy of Medicine.

Glenn Cohen, J.D.
Glenn is a Deputy Dean and Professor of
Law at Harvard Law School and the Faculty
Director for the Petrie-Flom Center for Health
Law Policy, Biotechnology, and Bioethics.
An award-winning academic and lawyer,
Glenn’s work has appeared in leading
publications and his amicus briefs have been discussed by theUnited States Supreme Court. His current research focuses on bigdata, health information technologies, research ethics, reproductive
technology, and health policy.

Freda Lewis-Hall, MD,
DFAPA, MFPM
During her 35-year career in medicine,
Dr. Freda Lewis-Hall has been on thefrontlines of health care as a clinician,educator, researcher, and leader in thebiopharmaceuticals and life sciencesindustries. Freda most recently served as Pfizer, Inc.’s Chief Medical
Officer and Executive Vice President until the end of 2018 and as
Chief Patient Officer and Executive Vice President during 2019.
In these roles, Freda expanded outreach to patients, reshaped
the focus on patient engagement and inclusion, improved healthinformation and education, and amplified the voice of the patient
within company culture and decision-making.

Nita Farahany, J.D., Ph.D.
Nita is the Robinson O. Everett Professorof Law & Philosophy at Duke University,and the Director of Duke Science & Society
Initiative. President Obama appointed Nita
to the Presidential Commission for the Studyof Bioethical Issues in 2010 and she served
until 2017. She is a leading scholar on the ethical, legal, and social
implications of biosciences and emerging technologies, particularly
those related to neuroscience and behavioral genetics.

Charmaine Royal, Ph.D.
Charmaine is an Associate Professor ofAfrican & African American Studies, Biology,
Global Health, and Family Medicine &Community at Duke University. She directs
the Center on Genomics, Race, Identity, andDifference and the Center for Truth, RacialHealing, and Transformation at the Social Science Research Institute.
Charmaine’s main academic interest is in addressing root causes andimplementing sustainable solutions regarding problems of race andracism in research, healthcare, and society.